Pfizer to buy obesity drug developer Metsera for up to $7.3 billion
rose in premarket trading after it announced that it would acquire anti-obesity drug developer , which puts the pharmaceutical giant back in the weight-loss medication game after its own pill didn’t a...
Who is winning the GLP-1 race?
It’s safe to say that investors are no longer as impressed by the massive sales drugmakers are raking in off blockbuster GLP-1 shots currently on the market — they’re thinking about what's coming next...
Novo jumps after Wegovy pill shows significant weight loss in trial, Ozempic found to reduce risk of heart attacks and strokes
Danish GLP-1 trailblazer was trading as much as 7% higher early on Thursday after releasing two positive study results. Arguably the most commercially significant of the two, Novo yesterday revealed ...
Moderna is up on the release of positive results for reformulated Covid vaccine
rose on Tuesday after it announced encouraging trial results for its next COVID-19 vaccine. The data from its phase 4 clinical trial showed the 2025-26 formula of its COVID-19 vaccine, which targets a...
Hims falls after FDA posts warning letter
fell by more than 5% after the US Food and Drug Administration posted a warning letter it sent the company over its compounded weight-loss drugs. In a letter dated September 9, the FDA took issue with...
Novo Nordisk’s GLP-1 pill gets EU approval for cardiovascular benefits
rose in early trading after it announced that European regulators approved its diabetes pill to be marketed for cardiovascular benefits as well. Rybelsus — a pill version of semaglutide, the active in...
Moderna, Pfizer dip after WaPo reports Trump officials’ plan to link Covid vaccines to child deaths
Vaccine makers are falling after The Washington Post reported that the Trump administration plans to link the coronavirus vaccine to 25 child deaths. and , the two companies who sell the vaccine in th...
Tempus AI jumps on FDA clearance of AI-enabled tool to analyze cardiac MRIs
, a midcap medical diagnostics company that’s highlighted a push to incorporate AI technology into its products, surged on Thursday after announcing the FDA had issued a “510(k) clearance” of a new AI...
Hims expands into testosterone treatments
rose more than 5% on Wednesday morning after it announced that it has expanded into testosterone treatments after teasing the new category earlier this year. Starting Wednesday, Hims providers will be...
Hims rises, Novo dips after FDA releases “green list” of GLP-1 raw material suppliers
rose and slipped in early trading after the US Food and Drug Administration released a " green list" of foreign GLP-1 ingredient suppliers that it considers in compliance with agency standards. Some ...
Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism
sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report. Kenvue, the maker...
Hims jumps as investors see litigation risk dwindling
rose more than 8% in early trading Wednesday after a judge dismissed a lawsuit by challenging a different telehealth company that sells knockoff versions of its GLP-1 drugs. Hims, the only publicly t...
Lilly reports positive final trial results for weight-loss pill, says it’s headed for regulatory approval
reported encouraging trial results for its next-generation weight-loss pill, putting it on track to file for regulatory approval by the end of the year. The pill, orforglipron, resulted in up to 10.5%...
Ro’s CEO on how GLP-1s built the framework for “pharm-to-table”
When President Trump demanded drugmakers slash prices for Americans, they leaned into a solution that didn’t involve slimming their margins: cutting out the middlemen. A running theme in large drugmak...
The GLP-1 biz keeps booming while drugmakers and telehealth companies have a food fight
Demand for blockbuster GLP-1 drugs has never been higher , creating opportunity for both the drugmakers that developed them and telehealth companies that sell compounded versions. But for these compan...
Viking Therapeutics tanks after weight-loss pill trial disappoints
dropped in premarket trading after it reported trial results for its weight-loss pill Tuesday morning that disappointed investors. The pill, dubbed VK2735, helped patients lose up to 12.2% of their bo...
Novo Nordisk slashes cost of weight-loss drugs for cash-paying customers in the US
Americans are getting cheaper access to blockbuster weight-loss drugs. The company announced Monday that cash-paying patients can get the diabetes/weight-loss drug Ozempic for $499 per month (half it...
Novo Nordisk rises after Wegovy gets FDA nod for liver disease
rose in premarket trading after its blockbuster weight-loss shot Wegovy was approved by the Food and Drug Administration to treat a liver condition. The company announced late Friday that Wegovy was g...
Gilead rises after earnings, revenue beat
rose in after-hours trading after it reported earnings and revenue results that exceeded Wall Street expectations. The drugmaker reported adjusted earnings per share of $2.01, flat year over year but ...
Eli Lilly craters after disappointing trial results for its GLP-1 pill, despite cheery earnings results
dropped sharply after it reported disappointing trial results for its next-gen weight-loss pill alongside earnings results that crushed Wall Street expectations thanks to its blockbuster GLP-1 drugs t...